Aims: This paper investigates the presence of M3 muscarinic acetylcholine receptor autoantibody present in the serum of patients with primary Sj？gren syndrome (pSS). Main methods: We detected the levels of M3mAChR peptide IgG, PGE2, IL-1β in serum of SS patients using the enzyme-linked immune sorbent assay (ELISA). To measure the quantity of nitrite/nitrate, we used Griess reagent system. Key findings: Titres of M3mAChR antibody in sera from SS patients are significantly enhanced compared to healthy subjects (control). The enhancement of these autoantibodies is accompanied by the increase of the levels of PGE2, IL-1β and nitrite/nitrate in serum. Under in vitro conditions, the synthetic human M3 peptide impaires the increment of M3mAChR antibody but not that of nati-Ro/SSA antibody. In positive anti-Ro/SSA antibody patients, the increment of M3mAChR peptide IgG and the measured pro-inflammatory substances is related. Significance: On this basis, anti M3mAChR peptide IgG can be said to act as a modulator of the immune system and to play a role in the host-chronic increment of proinflammatory substances in SS patients with positive Ro/SSA antibody. This association between the antibody and the pathogenesis of SS disease may result in useful predicting SS.
References
[1]
Mavragani, C.P. and Moutsopoulos, H.M. (2010) Thegeoepidemiology of SjÖgren’s Syndrome. Autoimmunity Review, 9, A305-A310.
https://doi.org/10.1016/j.autrev.2009.11.004
[2]
Theander, E., Henriksson, G., Ljungberg, O., Mandl, T., Manthorpe, R. and Jacobsson, L.T. (2006) Lymphoma and Other Malignancies in Primary SjÖgren’s Syndrome: A Cohort Study on Cancer Incidence and Lymphoma Predictors. Annals of Rheumatology Diseases, 65, 796-803. https://doi.org/10.1136/ard.2005.041186
[3]
Baimpa, E., Dahabreh, I.J., Voulgarelis, M. and Moutsopoulos, H.M. (2009) Hematologic Manifestations and Predictors of Lymphoma Development in Primary SjÖgren Syndrome: Clinical and Pathophysiologic Aspects. Medicine, 88, 284-293.
https://doi.org/10.1097/MD.0b013e3181b76ab5
[4]
Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H.M., Alexander, E.L., Carsons, S.E., Daniels, T.E., Fox, P.C., Fox, R.I., Kassan, S.S., Pillemer, S.R., Talal, N. and Weisman, M.H. (2002) Classification Criteria for SjÖgren’s Syndrome: A Revised Version of the European Criteria Proposed by the American-European Consensus Group. Annals of Rheumatology Diseases, 61, 554-558.
https://doi.org/10.1136/ard.61.6.554
[5]
Nardi, N., Brito-Zerón, P., Ramos-Casals, M., Aguiló, S., Cervera, R., Ingelmo, M. and Font, J. (2006) Circulating Auto-Antibodies against Nuclear and Non-Nuclear Antigens in Primary SjÖgren’s Syndrome: Prevalence and Clinical Significance in 335 Patients. Clinical Rheumatology, 25, 341-346.
https://doi.org/10.1007/s10067-005-0059-3
[6]
Reina, S., Sterin-Borda, L., Passafaro, D. and Borda, E. (2011) Anti-M(3) Muscarinic Cholinergic Autoantibodies from Patients with Primary SjÖgren’s Syndrome Trigger Production of Matrix Metalloproteinase-3 (MMP-3) and Prostaglandin E2 (PGE2) from the Submandibular Glands. Archives of Oral Biology, 5, 413-420.
https://doi.org/10.1016/j.archoralbio.2010.08.017
[7]
Passafaro, D., Reina, S., Sterin-Borda, L. and Borda, E. (2010) Cholinergic Autoantibodies from Primary SjÖgren’s Syndrome Modulate Submandibular Gland Na+/K+-ATPase Activity via Prostaglandin E2 and Cyclic AMP. European Journal of Oral Science, 118, 131-138. https://doi.org/10.1111/j.1600-0722.2010.00716.x
[8]
Park, K., Haberberger, R.V., Gordon, T.P. and Jackson, M.W. (2011) Antibodies Interfering with the Type 3 Muscarinic Receptor Pathway Inhibit Gastrointestinal Motility and Cholinergic Neurotransmission in SjÖgren’s Syndrome. Arthritis Rheumatology, 63, 1426-1434. https://doi.org/10.1002/art.30282
[9]
Reina, S., Sterin-Borda, L., Orman, B. and Borda, E. (2004) Autoantibodies against Cerebral Muscarinic Cholinoceptors in SjÖgren Syndrome: Functional and Pathological Implications. Journal of Neuroimmunology, 150, 107-115.
https://doi.org/10.1016/j.jneuroim.2004.01.019
[10]
Reina, S., Sterin-Borda, L., Orman, B. and Borda, E. (2004) Human mAChR Antibodies from SjÖgren Syndrome Sera Increase Cerebral Nitric Oxide Synthase Activity and Nitric Oxide Synthase mRNA Level. Clinical Immunology, 113, 193-202.
https://doi.org/10.1016/j.clim.2004.08.005
[11]
Routsias, J.G. and Tzioufas, A.G. (2007) SjÖgren’s Syndrome—Study of Autoantigens and Autoantibodies. Clinical Review of Allergy & Immunology, 232, 238-251.
https://doi.org/10.1007/s12016-007-8003-8
[12]
Simons, F.H., Pruijn, G.J. and van Venrooij, W.J. (1994) Analysis of the Intracellular Localization and Assembly of Ro Ribonucleoprotein Particles by Microinjection into Xenopuslaevis oocytes. Journal of Cell Biology, 125, 981-988.
https://doi.org/10.1083/jcb.125.5.981
[13]
Reina, S., Sterin-Borda, L. and Borda, E. (2012) Anti-M3 Peptide IgG from SjÖgren’s Syndrome Triggers Apoptosis in A253 Cells. Cell Immunology, 275, 33-41.
[14]
Espinosa, A., Zhou, W., Ek, M., Hedlund, M., Brauner, S., Popovic, K., Horvath, L., Wallerskog, T., Oukka, M., Nyberg, F., Kuchroo, V.K. and Wahren-Herlenius, M. (2006) The Sjogren’s Syndrome-Associated Autoantigen Ro52 Is an E3 Ligase That Regulates Proliferation and Cell Death. Journal of Immunology, 176, 6277-6285.
https://doi.org/10.4049/jimmunol.176.10.6277
[15]
Higgs, R., NíGabhann, J., Ben Larbi, N., Breen, E.P., Fitzgerald, K.A. and Jefferies, C.A. (2008) The E3 Ubiquitin Ligase Ro52 Negatively Regulates IFN-Beta Production Post-Pathogen Recognition by Polyubiquitin-Mediated Degradation of IRF3. Journal of Immunology, 181, 1780-1786.
https://doi.org/10.4049/jimmunol.181.3.1780
[16]
Higgs, R., Lazzari, E., Wynne, C., NíGabhann, J., Espinosa, A., Wahren-Herlenius, M. and Jefferies, C.A. (2010) Self Protection from Anti-Viral Responses—Ro52 Promotes Degradation of the Transcription Factor IRF7 Downstream of the Viral Toll-Like Receptors. PLoS ONE, 5, e11776. https://doi.org/10.1371/journal.pone.0011776
[17]
Oke, V. and Wahren-Herlenius, M. (2012) The Immunology of Ro52 in Autoimmunity: A Critical Review. Journal of Autoimmunity, 39, 77-82.
[18]
Martel, C., Gondran, G., Launay, D., Lalloué, F., Palat, S., Lambert, M., Ly, K., Loustaud-Ratti, V., Bezanahary, H., Hachulla, E., Jauberteau, M.O., Vidal, E., Hatron, P.Y. and Fauchais, A.L. (2011) Active Immunological Profile Is Associated with Systemic SjÖgren’s Syndrome. Journal of Clinical Immunology, 31, 840-847.
https://doi.org/10.1007/s10875-011-9553-3
[19]
Bacman, S., Sterin-Borda, L., Camusso, J.J., Hubscher, O., Arana, R. and Borda, E. (1994) Circulating Antibodies against Neurotransmitter Receptor Activities in Children with Congenital Heart Block and Their Mothers. FASEB Journal, 8, 1170-1176.
[20]
Brucato, A., Cimaz, R., Caporali, R., Ramoni, V. and Buyon, J. (2011) Pregnancy Outcomes in Patients with Autoimmune Diseases and Anti-Ro/SSA Antibodies. Clinical Review of Allergy & Immunology, 40, 27-41.
https://doi.org/10.1007/s12016-009-8190-6
[21]
Vitali, C., Bombardieri, S., Moutsopoulos, H.M., Balestrieri, G., Bencivelli, W., Bernstein, R.M., Bjerrum, K.B., Braga, S., Coll, J. and de Vita, S. (1993) Preliminary Criteria for the Classification of SjÖgren’s Syndrome. Results from a Prospective Concerted Action Supported by the European Community. Arthritis Rheumatology, 36, 340-347. https://doi.org/10.1002/art.1780360309
[22]
Green, L.C., Ruiz de Luzuriaga, K., Wagner, D.A., Rand, W., Istfan, N., Young, V.R. and Tannenbaum, S.R. (1981) Nitrate Biosynthesis in Man. Proceeding National Academic of Science, 78, 7764-7768. https://doi.org/10.1073/pnas.78.12.7764
[23]
Tatouli, I.P. and Tzioufas, A.G. (2012) Pathogenetic Aspects of Humoral Autoimmunity in SjÖgren’s Syndrome. Lupus, 21, 1151-1154.
https://doi.org/10.1177/0961203312458717
[24]
Stetson, D.B. (2009) Connections between Antiviral Defense and Autoimmunity. Current Opinion of Immunology, 21, 244-250.
[25]
Scofield, R.H., Kurien, B.T., Ganick, S., McClain, M.T., Pye, Q., James, J.A., Schneider, R.I., Broyles, R.H., Bachmann, M. and Hensley, K. (2005) Modification of Lupus-Associated 60-kDa Ro Protein with the Lipid Oxidation Product 4-Hydroxy-2-nonenal Increases Antigenicity and Facilitates Epitope Spreading. Free Ra-dical Biology & Medicine, 38, 719-728.
[26]
Bourré-Tessier, J., Clarke, A.E., Huynh, T., Bernatsky, S., Joseph, L., Belisle, P. and Pineau, C.A. (2011) Prolonged Corrected QT Interval in Anti-Ro/SSA-Positive Adults with Systemic Lupus Erythematosus. Arthritis Care Research, 63, 1031-1037.
https://doi.org/10.1002/acr.20470
[27]
Lazzerini, P.E., Capecchi, P.L., Acampa, M., Morozzi, G., Bellisai, F., Bacarelli, M.R., Dragoni, S., Fineschi, I., Simpatico, A., Galeazzi, M. and Laghi-Pasini, F. (2011) Anti-Ro/SSA-Associated Corrected QT Interval Prolongation in Adults: The Role of Antibody Level and Specificity. Arthritis Care Research, 63, 1463-1470.
https://doi.org/10.1002/acr.20540
[28]
Lazzerini, P.E., Capecchi, P.L., Guideri, F., Bellisai, F., Selvi, E., Acampa, M., Costa, A., Maggio, R., Garcia-Gonzalez, E., Bisogno, S., Morozzi, G., Galeazzi, M. and Laghi-Pasini, F. (2007) Comparison of Frequency of Complex Ventricular Arrhythmias in Patients with Positive versus Negative Anti-Ro/SSA and Connective Tissue Disease. American Journal of Cardiology, 100, 1029-1034.
[29]
Cain, B.S., Meldrum, D.R., Dinarello, C.A., Meng, X., Joo, K.S., Banerjee, A. and Harken, A.H. (1999) Tumor Necrosis Factor-Alpha and Interleukin-1beta Synergistically Depress Human Myocardial Function. Critical Care Medicine, 27, 1309-1318.
https://doi.org/10.1097/00003246-199907000-00018
